<DOC>
	<DOCNO>NCT00002948</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos drug kill tumor cell . PURPOSE : Phase I trial study effectiveness high-dose topotecan peripheral stem cell transplantation treat patient refractory cancer .</brief_summary>
	<brief_title>High-Dose Topotecan Peripheral Stem Cell Transplantation Treating Patients With Refractory Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose , toxicity , preliminary antitumor activity escalate dos topotecan , filgrastim ( G-CSF ) peripheral blood stem cell support , administer patient refractory malignancy effective therapy exists . OUTLINE : This dose-escalation study . Prior stem cell harvesting , patient receive 1-2 course mobilize salvage chemotherapy . After stem cell harvest , high-dose topotecan administer accord escalate dosage scale . Topotecan give 30 minute daily three day . A minimum 3 patient enter dose level . The MTD define dose immediately 2 patient experience dose limit toxicity . Peripheral blood stem cell ( PBSC ) infuse least 24 hour treatment topotecan complete . Filgrastim ( G-CSF ) administer subcutaneously begin day PBSC infuse continue blood count recover . Patients follow every 3 month 1 year every 6 month thereafter . PROJECTED ACCRUAL : Not specify</detailed_description>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm refractory malignancy effective therapy currently available PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Platelet count least 100,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Hepatic : Total bilirubin great 2.0 mg/dL No chronic active hepatitis Renal : Creatinine clearance least 60 mL/min Cardiovascular : Left ventricular ejection fraction great 45 % Pulmonary : DLCO great 60 % predict Other : HIV negative No active infection No concurrent medical condition would preclude therapy Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week since prior nitrosoureas mitomycin ) Endocrine therapy : Not specify Radiotherapy : No radiotherapy great 30 % bone marrow No wide field radiotherapy Surgery : Recovered prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>